Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.67 |
| ▸ | CA2 | P00918 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.55 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.55 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.53 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.53 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CHUK | O15111 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29848306 | 1.00 | CA1 (0.67) | CA1CA2MAPTPKMALDH1A1 | |
| SCHEMBL5302317 | 0.84 | CHUK (0.67) | CA1CA2P2RX1CHUKCLK1 | |
| SCHEMBL1071711 | 0.83 | KDM4E (0.52) | CA1CA2MAPTPKMALDH1A1 | |
| SCHEMBL3790275 | 0.82 | ALDH1A1 (0.60) | CA1CA2MAPTALDH1A1KDM4E | |
| SCHEMBL6966672 | 0.82 | CA1 (0.72) | CA1CA2MAPTPKMGAA | |
| SCHEMBL23463710 | 0.81 | CA1 (0.55) | CA1CA2MAPTPKMALDH1A1 | |
| SCHEMBL30219241 | 0.80 | ALDH1A1 (0.65) | MAPTALDH1A1KDM4EGLAGAA | |
| SCHEMBL1086528 | 0.80 | ALDH1A1 (0.65) | MAPTALDH1A1KDM4EGLAGAA | |
| SCHEMBL29769239 | 0.80 | CA1 (0.69) | CA1CA2MAPTPKMP2RX1 | |
| 5-Chlorosalicylic Acid SCHEMBL130605 | 0.80 | CA1 (1.00) | CA1CA2MAPTPKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 334 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3720493-B1 | COMBINATIONS OF RIPK1- AND IKK-INHIBITORS FOR THE PREVENTION OR TREATMENT OF IMMUNE DISEASES | UNIV KOELN (DE) | 2024-07-24 | — | — | EP | claimed |
| EP-4093401-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | The Board of Regents of the University of Texas System (US) | 2022-11-30 | — | — | EP | claimed |
| CN-114075146-A | Preparation method of deferasirox impurity | 江苏奥赛康药业有限公司 | 2022-02-22 | — | — | CN | claimed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| EP-1506196-B1 | PYRAZOLOPYRIMIDINES AS SODIUM CHANNEL INHIBITORS | ICAGEN INC (US) | 2012-01-18 | — | — | EP | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| CN-1964939-A | Compounds and compositions for delivering active agents | EMISPHERE TECH INC (US) | 2007-05-16 | — | — | CN | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| CN-1658872-A | Antiallergic agent | INST MED MOLECULAR DESIGN INC (JP) | 2005-08-24 | — | — | CN | claimed |
| US-20030216593-A1 | Method of preparing salicylamides | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2003-11-20 | — | — | US | claimed |
| WO-2001092206-A1 | METHOD OF PREPARING SALICYLAMIDES | EMISPHERE TECHNOLOGIES, INC. (US) | 2001-12-06 | — | — | WO | claimed |
| US-20260071218-A1 | Oral Delivery of Antisense Conjugates Targeting PCSK9 | CIVI BIOPHARMA INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20250319056-A1 | METHODS FOR TREATING CANCER | UNIV INDIANA TRUSTEES (US) | 2025-10-16 | — | — | US | disclosed |
| US-12291708-B2 | Oral delivery of antisense conjugates targeting PCSK9 | CIVI BIOPHARMA, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| CN-119661464-A | Efficient preparation method of chlorzoxazone | 山东新时代药业有限公司 | 2025-03-21 | — | — | CN | disclosed |
| US-4122049-A | Process for the production of polyurethane foam | BAYER AKTIENGESELLSCHAFT (DE) | 1978-10-24 | — | — | US | disclosed |
| US-4082751-A | ANTIALLERGENS | BRISTOL-MYERS COMPANY (US) | 1978-04-04 | — | — | US | disclosed |
| US-4031093-A | ANTIALLERGENS | BRISTOL-MYERS COMPANY (US) | 1977-06-21 | — | — | US | disclosed |
| US-3968104-A | SOLVENTS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260071218-A1 | Oral Delivery of Antisense Conjugates Targeting PCSK9 | PCSK9, ALPI, SLC10A2 | CA1 1982/4885CA2 836/4885MAPT 2115/4885 |
| US-20030216593-A1 | Method of preparing salicylamides | SCLY, ADSL, SIK3 | CA1 129/4885CA2 96/4885MAPT 4132/4885 |
| US-20250319056-A1 | METHODS FOR TREATING CANCER | HSP90AB1, HSP90B1, HSP90AB2P | CA1 2679/4885CA2 2002/4885MAPT 1446/4885 |
| US-12291708-B2 | Oral delivery of antisense conjugates targeting PCSK9 | PCSK9, SCD5, PCSK7 | CA1 2704/4885CA2 1578/4885MAPT 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.